Vascular endothelial growth factor receptor, Platelet-derived growth factor receptor, and Stem cell factor receptor (c-Kit) (VEGFR/PDGFR/c-Kit)

The VEGFR/PDGFR/c-Kit target profile represents a cluster of receptor tyrosine kinases (RTKs) that are critical regulators of tumor angiogenesis, stromal support, and cellular proliferation. Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and -3) are the primary drivers of blood and lymphatic vessel formation, which are essential for supplying nutrients to growing tumors [5, 7]. Platelet-Derived Growth Factor Receptors (PDGFR-alpha and -beta) contribute to the recruitment of pericytes and fibroblasts, stabilizing the tumor microenvironment and promoting interstitial pressure that can influence drug delivery [7, 11]. The Stem Cell Factor Receptor (c-Kit) is involved in the survival and maintenance of various cell types, including hematopoietic stem cells and certain malignant cells [9, 12]. Drugs like pazopanib function as multi-kinase inhibitors by binding to the ATP-binding pocket of these receptors, thereby disrupting downstream signaling pathways such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR [10, 11]. This multi-targeted approach is particularly effective in treating highly vascularized malignancies like renal cell carcinoma and soft tissue sarcomas, where it simultaneously inhibits the tumor's blood supply and its intrinsic growth signals [6, 8].

Other names

VEGFR1VEGFR2VEGFR3PDGFR-alphaPDGFR-betaKITCD117FLT1KDRFLT4PDGFRAPDGFRBStem cell factor receptorMast/stem cell growth factor receptor Kit

Competitive inhibition of the adenosine triphosphate (ATP) binding site on the intracellular tyrosine kinase domain of the receptors, preventing autophosphorylation and downstream signaling cascades.